| CAS ID: | 884502-91-4 |
| Molecular Formula: | |
| Molecular Weight: | g/mol |
| Monoisotopic Mass: | g/mol |
| Class: | Other |
| Natural Product: | No |
| Other Names: | THERACLEC | ALTU-135 | LIPROTAMASE | TRIZYTEK |
| Analysis: | N/A |
Trial Record 1
| ClinicalTrial ID | NCT00449878 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 21, 2007 | Last Verified | October 24, 2014 |
| Sponsor | Anthera Pharmaceuticals | ||
Trial Record 2
| ClinicalTrial ID | NCT00095732 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 9, 2004 | Last Verified | October 17, 2014 |
| Sponsor | Anthera Pharmaceuticals | ||
Trial Record 3
| ClinicalTrial ID | NCT02734810 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | April 12, 2016 | Last Verified | May 11, 2018 |
| Sponsor | Anthera Pharmaceuticals | ||
Trial Record 4
| ClinicalTrial ID | NCT02279498 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 31, 2014 | Last Verified | August 14, 2018 |
| Sponsor | Anthera Pharmaceuticals | ||
Trial Record 5
| ClinicalTrial ID | NCT00449904 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 21, 2007 | Last Verified | October 24, 2014 |
| Sponsor | Anthera Pharmaceuticals | ||
Trial Record 6
| ClinicalTrial ID | NCT02823964 | Disease | Cystic fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | July 6, 2016 | Last Verified | May 17, 2018 |
| Sponsor | Anthera Pharmaceuticals | ||
Trial Record 7
| ClinicalTrial ID | NCT03051490 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Active, not recruiting |
| First Received | February 13, 2017 | Last Verified | March 8, 2018 |
| Sponsor | Anthera Pharmaceuticals | ||
| PubChem: | 96026036 |
| ChEMBL: | CHEMBL2108703 |